Sana Biotechnology (SANA) Competitors

$3.06 +0.02 (+0.66%)

Closing price 05/19/2026 04:00 PM Eastern

Extended Trading

$3.06 0.00 (-0.16%)

As of 05/19/2026 07:38 PM Eastern

SANA vs. NNNN, VKTX, TLX, TWST, and OGN

Should you buy Sana Biotechnology stock or one of its competitors? MarketBeat compares Sana Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sana Biotechnology include Anbio Biotechnology (NNNN), Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Twist Bioscience (TWST), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.

How does Sana Biotechnology compare to Anbio Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Anbio Biotechnology's return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Anbio Biotechnology	N/A	N/A	N/A

Sana Biotechnology has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its share price is 371% more volatile than the broader market.

Anbio Biotechnology has higher revenue and earnings than Sana Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Anbio Biotechnology	$8.65M	537.97	$6.40M	N/A	N/A

In the previous week, Sana Biotechnology had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for Sana Biotechnology and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 0.93 beat Sana Biotechnology's score of -0.02 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.2% of Sana Biotechnology shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sana Biotechnology presently has a consensus target price of $9.50, indicating a potential upside of 210.46%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe Sana Biotechnology is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sana Biotechnology and Anbio Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

How does Sana Biotechnology compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

In the previous week, Sana Biotechnology had 6 more articles in the media than Viking Therapeutics. MarketBeat recorded 11 mentions for Sana Biotechnology and 5 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.11 beat Sana Biotechnology's score of -0.02 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Viking Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market.

Viking Therapeutics currently has a consensus target price of $95.50, suggesting a potential upside of 236.27%. Sana Biotechnology has a consensus target price of $9.50, suggesting a potential upside of 210.46%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Viking Therapeutics' return on equity of -71.31% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Sana Biotechnology	N/A	-108.01%	-40.68%

Summary

Sana Biotechnology beats Viking Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Sana Biotechnology (NASDAQ:SANA) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Telix Pharmaceuticals	$803.79M	4.29	-$7.12M	N/A	N/A

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Telix Pharmaceuticals	N/A	N/A	N/A

Sana Biotechnology has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

Sana Biotechnology currently has a consensus price target of $9.50, suggesting a potential upside of 210.46%. Telix Pharmaceuticals has a consensus price target of $21.13, suggesting a potential upside of 107.72%. Given Sana Biotechnology's higher possible upside, research analysts clearly believe Sana Biotechnology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

88.2% of Sana Biotechnology shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Sana Biotechnology had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 11 mentions for Sana Biotechnology and 4 mentions for Telix Pharmaceuticals. Sana Biotechnology's average media sentiment score of -0.02 beat Telix Pharmaceuticals' score of -0.04 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Telix Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Sana Biotechnology compare to Twist Bioscience?

Sana Biotechnology (NASDAQ:SANA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 210.46%. Twist Bioscience has a consensus target price of $56.57, suggesting a potential upside of 14.29%. Given Sana Biotechnology's higher possible upside, equities analysts clearly believe Sana Biotechnology is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Sana Biotechnology has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Sana Biotechnology has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market.

In the previous week, Sana Biotechnology had 6 more articles in the media than Twist Bioscience. MarketBeat recorded 11 mentions for Sana Biotechnology and 5 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.46 beat Sana Biotechnology's score of -0.02 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Twist Bioscience	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.2% of Sana Biotechnology shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Twist Bioscience has higher revenue and earnings than Sana Biotechnology. Twist Bioscience is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Twist Bioscience	$376.57M	8.19	-$77.67M	-$1.33	N/A

Summary

Sana Biotechnology and Twist Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Organon & Co. has a net margin of 3.99% compared to Sana Biotechnology's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Sana Biotechnology	N/A	-108.01%	-40.68%

In the previous week, Sana Biotechnology had 5 more articles in the media than Organon & Co.. MarketBeat recorded 11 mentions for Sana Biotechnology and 6 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.79 beat Sana Biotechnology's score of -0.02 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	1 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Organon & Co. has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.45
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Organon & Co. currently has a consensus target price of $11.40, indicating a potential downside of 15.15%. Sana Biotechnology has a consensus target price of $9.50, indicating a potential upside of 210.46%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Organon & Co. beats Sana Biotechnology on 8 of the 15 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$846.01M	$3.25B	$6.25B	$12.23B
Dividend Yield	N/A	2.34%	2.80%	5.32%
P/E Ratio	-3.29	18.52	20.79	25.05
Price / Sales	N/A	270.32	531.21	72.69
Price / Cash	N/A	124.58	43.09	54.25
Price / Book	7.12	6.60	9.81	6.83
Net Income	-$244.17M	$24.18M	$3.55B	$335.69M
7 Day Performance	-4.38%	-3.74%	-2.12%	-2.15%
1 Month Performance	-19.90%	-7.95%	-4.14%	-2.47%
1 Year Performance	46.41%	50.32%	28.34%	27.13%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	2.6023 of 5 stars	$3.06 +0.7%	$9.50 +210.5%	+82.1%	$846.01M	N/A	N/A	380	Gap Down
NNNN Anbio Biotechnology	1.4139 of 5 stars	$25.35 -1.9%	N/A	N/A	$3.72B	$8.65M	N/A	27	News Coverage Gap Up
VKTX Viking Therapeutics	3.7436 of 5 stars	$31.72 +1.2%	$95.50 +201.1%	+3.3%	$3.64B	N/A	N/A	20
TLX Telix Pharmaceuticals	4.4322 of 5 stars	$10.83 +1.4%	$21.13 +95.1%	-38.5%	$3.62B	$803.79M	N/A	1,184	Positive News
TWST Twist Bioscience	2.2745 of 5 stars	$56.21 -1.1%	$56.57 +0.6%	+62.9%	$3.54B	$376.57M	N/A	990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. NNNN, VKTX, TLX, TWST, and OGN

How does Sana Biotechnology compare to Anbio Biotechnology?

Summary

How does Sana Biotechnology compare to Viking Therapeutics?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Summary

How does Sana Biotechnology compare to Twist Bioscience?

Summary

How does Sana Biotechnology compare to Organon & Co.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. NNNN, VKTX, TLX, TWST, and OGN

How does Sana Biotechnology compare to Anbio Biotechnology?

Is SANA or NNNN more profitable?

Which has more risk and volatility, SANA or NNNN?

Which has better earnings & valuation, SANA or NNNN?

Does the media favor SANA or NNNN?

Do institutionals & insiders believe in SANA or NNNN?

Do analysts recommend SANA or NNNN?

Summary

How does Sana Biotechnology compare to Viking Therapeutics?

Does the media prefer VKTX or SANA?

Do insiders and institutionals hold more shares of VKTX or SANA?

Which has preferable valuation & earnings, VKTX or SANA?

Which has more risk and volatility, VKTX or SANA?

Do analysts rate VKTX or SANA?

Is VKTX or SANA more profitable?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Which has stronger earnings and valuation, SANA or TLX?

Is SANA or TLX more profitable?

Which has more volatility and risk, SANA or TLX?

Do analysts rate SANA or TLX?

Do insiders & institutionals hold more shares of SANA or TLX?

Does the media prefer SANA or TLX?

Summary

How does Sana Biotechnology compare to Twist Bioscience?

Do analysts recommend SANA or TWST?

Is SANA or TWST more profitable?

Which has more volatility and risk, SANA or TWST?

Does the media favor SANA or TWST?

Do institutionals and insiders hold more shares of SANA or TWST?

Which has preferable valuation & earnings, SANA or TWST?

Summary

How does Sana Biotechnology compare to Organon & Co.?

Do institutionals & insiders believe in OGN or SANA?

Is OGN or SANA more profitable?

Does the media prefer OGN or SANA?

Which has more volatility and risk, OGN or SANA?

Which has stronger earnings & valuation, OGN or SANA?

Do analysts rate OGN or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools